Wire · regulatory
FDA Approves Talzenna Combination for Advanced Prostate Cancer with Certain Gene Mutations
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 October 2026 · Fusion42 review
The FDA approved the combination of talazoparib (Talzenna) with enzalutamide for adults with metastatic prostate cancer having certain homologous recombination repair (HRR) gene mutations, based on a trial showing a 52% reduction in cancer progression risk. This approval includes an FDA-authorized companion diagnostic test to identify eligible patients and applies to those treatment-naïve or sensitive to androgen pathway modulation.
This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 26 Oct 2026 and 28 Oct 2026.
◆ ◆ The Wire takeaway
This FDA approval opens a new precision treatment route for metastatic prostate cancer marked by HRR mutations, making companion diagnostic testing a market entry point. You need to prioritise partnerships with labs and oncologists to unlock patient access and navigate safety and monitoring complexities.
◆ Coverage
10 sources · first reported 26 Oct 2026 · latest 28 Oct 2026
◆ Related on Wire
◆ Topics